Ciforadenant

DB16125InvestigationalSmall molecule

Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).

Mechanism: Pharmacologically active on Adenosine receptor A2a
Curator reviewed
Formula / weight: C₂₀H₂₁N₇O₃ · 407.434 g/mol (avg)
Code names: CPI-444 · V-81444

Resolves to

Compound

UNII8KFO2187CPCAS1202402-40-1ChEMBLCHEMBL4297184

Structure

InChIKeyKURQKNMKCGYWRJ-HNNXBMFYSA-NSMILESCC1=CC=C(O1)C1=C2N=NN(CC3=CC=CC(CO[C@H]4CCOC4)=N3)C2=NC(N)=N1

Targets

P29274ADORA2A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ciforadenant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account